| Cardiovascular Diabetology | |
| Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme | |
| Original Investigation | |
| Maximilian von Eynatten1  Hans-Juergen Woerle1  Sanjay Patel2  Dietmar Neubacher3  Odd Erik Johansen4  | |
| [1] Boehringer Ingelheim GmbH, Ingelheim, Germany;Boehringer Ingelheim Ltd, Bracknell, Berkshire, UK;Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany;Boehringer Ingelheim, Asker, Norway; | |
| 关键词: Cardiovascular risk; DPP-4 inhibitor; linagliptin; meta-analysis; type 2 diabetes mellitus; | |
| DOI : 10.1186/1475-2840-11-3 | |
| received in 2011-10-18, accepted in 2012-01-10, 发布年份 2012 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundThis study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments.MethodsThis was a pre-specified meta-analysis of CV events in linagliptin or comparator-treated patients with type 2 diabetes mellitus (T2DM) from eight Phase 3 studies. All suspected CV events were prospectively adjudicated by a blinded independent expert committee. The primary endpoint was a composite of CV death, stroke, myocardial infarction, and hospitalization for unstable angina. Three secondary composite endpoints derived from the adjudicated CV events were also pre-specified. Risk estimates were calculated using several statistical methods including Cox regression analysis.ResultsOf 5239 treated patients (mean ± SD HbA1c 65 ± 10 mmol/mol [8.0 ± 0.9%], age 58 ± 10 years, BMI 29 ± 5 kg/m2), 3319 received linagliptin once daily (5 mg, 3159; 10 mg, 160) and 1920 received comparators (placebo, 977; glimepiride 1-4 mg, 781; voglibose 0.6 mg, 162). Cumulative exposure (patient-years) was 2060 for linagliptin and 1372 for comparators. Primary CV events occurred in 11 (0.3%) patients receiving linagliptin and 23 (1.2%) receiving comparators. The hazard ratio (HR) for the primary endpoint showed significantly lower risk with linagliptin than comparators (HR 0.34 [95% confidence interval (CI) 0.16-0.70]) as did estimates for all secondary endpoints (HR ranging from 0.34 to 0.55 [all upper 95% CIs < 1.0]).ConclusionsThese results from a large Phase 3 programme support the hypothesis that linagliptin may have CV benefits in patients with T2DM.
【 授权许可】
CC BY
© Johansen et al; licensee BioMed Central Ltd. 2012
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311101684885ZK.pdf | 638KB |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
PDF